Lymphoma  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

15 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00086840: CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Terminated
2
60
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia
08/05
 
NCT00033267: CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Completed
2
27
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma
02/06
02/08
NCT00109967: CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Checkmark P2 data
Mar 2011 - Mar 2011: P2 data
Completed
2
71
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma
09/09
03/12
NCT00290472: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed
2
89
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Malignant Neoplasm, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
04/10
04/10
NCT01281917: Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Completed
2
40
US
Velcade, bortezomib, PS-341, Temsirolimus, Torisel
University of Wisconsin, Madison, Millennium Pharmaceuticals, Inc., Pfizer, National Cancer Institute (NCI)
Non-Hodgkins Lymphoma
10/13
06/14
NCT00942747 / 2009-011277-33: Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Unknown status
2
37
Europe
temsirolimus, Torisel, CCI-770
Charite University, Berlin, Germany, Pfizer
Recurrent or Refractory Primary CNS Lymphoma
12/13
06/14
NCT01381692: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Completed
2
9
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
12/14
09/21
NCT00838955: Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Terminated
2
14
US
Temsirolimus
Loyola University, Wyeth is now a wholly owned subsidiary of Pfizer
Hodgkin's Lymphoma
10/16
10/17
STORM, NCT01653067 / 2011-001491-20: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Unknown status
2
88
Europe
Rituximab, Temsirolimus, DHAP, intravenous, Temsirolimus-R-DHAP, Torisel, MabThera, Fortecortin, ARA-C, ARA-cell, Depocyte, R-DHAP, Rituximab-DHAP, Temsirolimus,Rituximab,Dexamethasone,Cisplatine,Cytarabine, Temsirolimus-Rituximab-DHAP
Mathias Witzens-Harig, Johannes Gutenberg University Mainz, Technische Universität München, Ludwig-Maximilians - University of Munich, University Hospital Ulm, University Hospital Erlangen, Charite University, Berlin, Germany, University Hospital Freiburg, Johann Wolfgang Goethe University Hospital
Diffuse Large B-Cell Lymphoma
06/18
07/18
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
NCT00787969: Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Checkmark For initial therapy of mantle cell lymphoma
Jul 2014 - Jul 2014: For initial therapy of mantle cell lymphoma
Completed
1/2
74
US
rituximab, cladribine, temsirolimus, Filgrastim, Pegfilgrastim
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Lymphoma
04/12
06/17
NCT01170052 / 2009-014844-13: Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Withdrawn
1/2
20
Europe
Temsirolimus, Torisel®, Bendamustine
Charite University, Berlin, Germany, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma K.K.
Mantle Cell Lymphoma
04/12
04/14
NCT01389427: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Completed
1/2
41
Europe
Torisel dose 15 mg and R-CHOP, Arm A cohort -1, Torisel dose 15 mg and R-FC, Arm B cohort -1, Torisel dose 15 mg and R-DHA, Arm C cohort -1, Torisel dose 25 mg and R-CHOP, Arm A cohort 1, Torisel dose 50 mg and R-CHOP, Arm A cohort 2, Torisel dose 75 mg and R-CHOP, Arm A cohort 3, Torisel dose 25 mg and R-FC, Arm B cohort 1, Torisel dose 50 mg and R-FC, Arm B cohort 2, Torisel dose 75 mg and R-FC, Arm B cohort 3, Torisel dose 25 mg and R-DHA, Arm C cohort 1, Torisel dose 50 mg and R-DHA, Arm C cohort 2, Torisel 75 mg and R-DHA, Arm C cohort 3
The Lymphoma Academic Research Organisation, French Innovative Leukemia Organisation
Mantle Cell Lymphoma Refractory
05/15
09/15
BERT, NCT01078142 / 2009-013351-30: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Checkmark Interim P1/2 data in FL, MCL
Nov 2011 - Nov 2011: Interim P1/2 data in FL, MCL
Completed
1/2
39
Europe
Temsirolimus, Rituximab, Bendamustin, Mabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda
Georg Hess, MD, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma Pte Ltd.
Follicular Lymphoma, Mantle Cell Lymphoma
09/17
09/17

Download Options